Further work is required to identify the precise mechanism(s) by which CDK2 inhibition mediates the preservation and the increase of pathogen-specific and leukemia-specific effectors, while suppressing activation and expansion of alloreactive effectors, as well as to confirm these results in vivo. Here, CDK2 is linked to leukemia.